No Data
Is Lushang Freda PharmaceuticalLtd (SHSE:600223) A Risky Investment?
Freda: Lushang Freda Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Announcement of Lushang Freda Pharmaceutical Co., Ltd. on the main operating data for the first quarter of 2025
Lushang Freda Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Lushang Freda Pharmaceutical (600223.SH): In the first quarter, the net income was 50.71 million yuan, a year-on-year decrease of 14.1%.
On April 24, Gelonghui announced the first quarter report for Lushang Freda Pharmaceutical (600223.SH), with revenue of 0.876 billion yuan, a year-on-year decrease of 1.63%. The net income attributable to shareholders of the listed company was 50.71 million yuan, down 14.1% year-on-year, while the net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 46.99 million yuan, a year-on-year decrease of 9.67%.
Lushang Freda Pharmaceutical (600223.SH): Actively cultivating the second growth curve of collagen in medical aesthetics.
On April 24, Gelonghui reported that Lushang Freda Pharmaceutical (600223.SH) stated on the investor interaction platform that the company is actively cultivating the second growth curve of medical beauty collagen. The company has completed the construction of an intelligent production base for collagen medical instruments, making it the first comprehensive Industry Chain production base for recombinant humanized collagen in ShanDong. The planned production capacity of this base can reach 60 million units. The company has launched a medical beauty brand, Key C, centered on recombinant humanized type III collagen, with an online and offline multi-channel layout, entering platforms like Douyin and Xiaohongshu online, and leveraging medical beauty Institutions offline.
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157%
